View Document Preview and Link Document Date: 2014-10-17 08:15:10 Open Document File Size: 222,90 KB Share Result on Facebook
City Berlin / Cambridge / EPZ / / Company Eisai / Epizyme Inc. / / Country Germany / United States / / / Event FDA Phase / / IndustryTerm stage biopharmaceutical company creating / therapeutics for patients with genetically defined cancers / treatment of non- ‐Hodgkin lymphoma / cancer treatment / / MedicalCondition cancers / cancer / Hodgkin lymphomas / genetically defined cancers / advanced solid tumors / soft tissue sarcoma / solid tumors / human cancers / cell lymphomas / malignant rhabdoid tumors / Hodgkin lymphoma / Synovial sarcomas / deficient cancers / dependent tumor / synovial sarcoma / deficiency / / MedicalTreatment chemotherapy / / OperatingSystem CTOS / / Organization Securities and Exchange Commission / / Person Keilhack / / / Position Director of Biological Sciences / Private / / Product EPZ / / ProvinceOrState Massachusetts / / Technology gene expression / chemotherapy / pdf / / URL http / SocialTag 
Epizyme
Presents
Pre-‐Clinical
Data
on
EZH2
Inhibitor
EPZ-‐6438
(E7438)
in
Models
of
Synovial
Sarcoma